Composition and maturity are shared publicly. Program-level detail is reserved for qualified partners under NDA.
Given the competitive sensitivity of 505(b)(2) development, we share pipeline composition and maturity publicly, and reserve program-level detail for qualified partners.
Injectable, sterile, and lyophilised figures reflect active pipeline programs. Oral solids figure reflects total products developed to date.
Program-level detail — including target product profiles, regulatory pathway, and development timelines — is available to qualified partners and investors under a mutual NDA.